MedPath

Deucrictibant Shows Promising Long-term Safety and Efficacy in Hereditary Angioedema Treatment

• Pharvaris's oral drug deucrictibant demonstrated strong efficacy in Phase 3 studies, with patients experiencing a median of zero attack days per month during long-term prophylactic treatment.

• The medication showed consistent safety and efficacy in treating both upper airway and non-upper airway HAE attacks, with rapid and complete symptom resolution using a single dose.

• Clinical data revealed significant improvements in patients' quality of life, particularly in functioning and psychological aspects, addressing key concerns in the HAE community.

Pharvaris announced compelling safety and efficacy data for deucrictibant, their investigational oral treatment for Hereditary Angioedema (HAE), at the 2025 American Academy of Allergy, Asthma, & Immunology's Annual Scientific Meeting and World Allergy Organization Joint Congress in San Diego.
The drug, currently under evaluation in two pivotal Phase 3 studies, has demonstrated remarkable effectiveness in both prophylactic and on-demand treatment settings. Long-term prophylactic use resulted in patients experiencing a median of zero days with attack symptoms per month, marking a significant advancement in HAE management.

Clinical Efficacy in Upper Airway Attacks

Particularly noteworthy was deucrictibant's performance in treating upper airway attacks, including laryngeal episodes, which can be life-threatening. Data from seven documented upper airway attacks showed consistent efficacy with the results observed in 328 non-upper airway attacks, demonstrating rapid and complete symptom resolution with just a single dose.

Quality of Life Improvements

The clinical trials revealed substantial improvements in health-related quality of life (HRQoL) measures. Patients reported enhanced outcomes specifically in 'functioning' and 'fear and shame' domains, addressing critical psychological and practical challenges faced by the HAE community.

Expert Perspective

"Topline results of deucrictibant in both prophylactic and on-demand randomized clinical trials substantiate our belief in the mechanism and molecule to provide choice to those living with HAE," stated Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. He emphasized the significance of the long-term dosing data in supporting deucrictibant's potential to address unmet needs in HAE treatment.

Innovation in HAE Treatment

The development of deucrictibant represents a potential breakthrough in HAE therapy, offering what could be the first oral option for both prevention and acute treatment. This dual functionality, combined with the convenience of oral administration and single-dose efficacy, could significantly improve the standard of care for HAE patients.
The ongoing Phase 3 studies aim to confirm these promising findings and potentially establish deucrictibant as a transformative treatment option in the HAE therapeutic landscape.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Pharvaris Expands Deucrictibant Development to Acquired Angioedema Following Promising Early Data

Pharvaris announces plans to initiate a clinical trial for deucrictibant in acquired angioedema, expanding beyond its ongoing Phase 3 trials in hereditary angioedema. The decision follows encouraging results in three patients, as the company advances its bradykinin B2 receptor antagonist program with both immediate and extended-release formulations.

Dupixent Shows Positive Phase 3 Results for Chronic Spontaneous Urticaria

Dupixent significantly reduced itch and urticaria activity in patients with uncontrolled chronic spontaneous urticaria (CSU) in the Phase 3 LIBERTY-CUPID Study C.
The study demonstrated that a higher proportion of patients treated with Dupixent achieved well-controlled disease status compared to those receiving a placebo.

Dupixent Shows Positive Phase 3 Results in Chronic Spontaneous Urticaria

Phase 3 LIBERTY-CUPID Study C demonstrates Dupixent significantly reduces itch and urticaria activity in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU).
At 24 weeks, Dupixent showed significant improvements in itch severity, urticaria activity score, well-controlled disease status, and complete response compared to placebo.

Dupixent Shows Positive Phase 3 Data in Chronic Spontaneous Urticaria

Dupixent significantly reduced itch and hive activity from baseline in patients with chronic spontaneous urticaria (CSU) inadequately controlled by antihistamines.
41% of patients treated with Dupixent achieved well-controlled disease status compared to 23% on placebo, indicating a significant improvement.

Dupixent Shows Positive Phase 3 Results in Chronic Spontaneous Urticaria

Dupixent significantly reduced itch and urticaria activity scores in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU).
A higher proportion of patients treated with Dupixent achieved well-controlled disease status compared to placebo at 24 weeks.

Dupixent Shows Positive Phase 3 Results in Chronic Spontaneous Urticaria

Dupixent significantly reduced itch and hive activity in patients with chronic spontaneous urticaria (CSU) inadequately controlled by antihistamines.
41% of patients treated with Dupixent achieved well-controlled disease status compared to 23% on placebo, marking a significant improvement.

Dupixent Shows Positive Phase 3 Data for Chronic Spontaneous Urticaria

Dupixent significantly reduced itch and hive activity in patients with chronic spontaneous urticaria (CSU) inadequately controlled by antihistamines.
41% of patients treated with Dupixent achieved well-controlled disease status compared to 23% on placebo in the Phase 3 LIBERTY-CUPID Study C.

Bimekizumab Shows Sustained Efficacy in Hidradenitis Suppurativa Over Two Years

Two-year data from Phase 3 BE HEARD I and II trials demonstrate bimekizumab's sustained efficacy in treating moderate to severe hidradenitis suppurativa (HS).
85.4% of patients achieved HiSCR50 at week 96, indicating a substantial reduction in HS symptoms, while 77.1% reached HiSCR75.

Deucrictibant Shows Sustained Benefits in Hereditary Angioedema Treatment

Data from open-label extensions of Phase 2 trials demonstrate deucrictibant's sustained efficacy in preventing and treating swelling attacks associated with hereditary angioedema (HAE).
Results showed a 93% reduction in HAE attack rates after one year in the extension period, with a median monthly attack rate of zero.

KalVista's Sebetralstat Shows Consistent Efficacy for Hereditary Angioedema

KalVista Pharmaceuticals presented data at the Bradykinin Symposium 2024, highlighting sebetralstat's consistent efficacy and safety in treating hereditary angioedema (HAE) attacks.
Clinical trials showed sebetralstat provided rapid symptom relief, with a median time to relief of 1.8 hours for all attacks and 1.3 hours for laryngeal attacks.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy